Nasdaq vktx.
Feb 28, 2023 · 784,592. 4.713748. Back to VKTX Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a San Diego, California-based biotech company developing therapeutics for patients that are suffering from endocrine and metabolic disorders.Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added 15% on Monday after Roche (OTCQX:RHHBY) agreed to acquire a peer obesity drugmaker Carmot Therapeutics in a up to $3.1B deal. Viking ...SAN DIEGO, Nov. 28, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Viking Therapeutics, Inc. (NASDAQ:VKTX) is developing treatments for liver diseases, post surgical complications, and other ailments. Despite a hefty short interest percentage, ...
Oct 18, 2023 · Viking Therapeutics (NASDAQ:VKTX) is arguably best known for being one of the frontrunners to win the "NASH Dash," i.e. the first company to secure approval to market and sell a drug designed to ...
Viking Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. VKTX updated stock price target summary.Dec 1, 2023 · 9 brokers have issued 1 year target prices for Viking Therapeutics' shares. Their VKTX share price targets range from $19.00 to $37.00. On average, they predict the company's stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price.
Jul 10, 2023 · Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Quantitative Momentum Investor model based on the ... Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.The public float for VKTX is 89.39M and currently, short sellers hold a 18.98% ratio of that float. The average trading volume of VKTX on December 04, 2023 was 2.05M shares. VKTX) stock’s latest price update. Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 9.99relation to previous closing price of 13.01.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb …
Viking Therapeutics (NASDAQ:VKTX) spiked in late December, due to recent news indirectly related to the biopharma firm, and its efforts to bring a treatment for non-alcoholic steatohepatitis (or ...
VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...
According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Stock Information NASDAQVKTX $12.52 NASDAQVKTX Open $12.01 Change $0.69 (5.83%) Day's Range $12.01 - $12.67 52-Week Range $3.54 - $25.72 Volume 562.4K …Jan 3, 2023 · Rasi Bhadramani. Viking Therapeutics (NASDAQ:VKTX) has been my top NASH stock for the past few years due to VK2809's performance, the company's cash position, and the reasonable valuation ... About Institutional Holdings. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and ...Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.Benzinga. Nov. 14, 2023, 11:42 AM. Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company presented new data from its Phase 2b study of VK2809. What To Know ...
Simply Wall St ™. Simply Wall Street Pty Ltd. Level 7, 320 Pitt Street, Sydney. Popular Markets. US AU UK IN CA ZA. About Us Careers. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927).VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83. Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Quantitative Momentum Investor model based on the ...Nov 28, 2023 · See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Viking Therapeutics' (NASDAQ:VKTX) shares rose 14% after clinical results from a Phase 1 trial on its obesity drug, VK2735, were released. The study showed that VK2735, ...
As of April 24, 2023, the average one-year price target for Viking Therapeutics is 27.64. The forecasts range from a low of 19.19 to a high of $36.75. The average price target represents an ...
Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Quantitative Momentum Investor model based on the ...Jan 3, 2023 · Rasi Bhadramani. Viking Therapeutics (NASDAQ:VKTX) has been my top NASH stock for the past few years due to VK2809's performance, the company's cash position, and the reasonable valuation ... The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023. The analyst firm set a price target ...Dec 1, 2023 · In the previous quarter, Viking Therapeutics (NASDAQ:VKTX) missed the analysts' consensus estimate of ($0.22) by $0.01 with a reported earnings per share (EPS) of ($0.23). Learn more on analysts' earnings estimate vs. VKTX's actual earnings. The latest price target for . Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023.The analyst firm set a price target for 32.00 expecting VKTX to rise ...Apr 24, 2023 · Fintel reports that on April 25, 2023, Oppenheimer maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Outperform recommendation.. Analyst Price Forecast Suggests 29.59% Upside. As of ...
Viking Therapeutics, Inc. Common Stock (VKTX). Nasdaq Listed ...
VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.
SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...Nov 29, 2023 · Real time Viking Therapeutics (VKTX) stock price quote, stock graph, news & analysis. View real-time VKTX stock price and news, ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with volume of at least 50,000.Market Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes.Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ... Nasdaq Futures. 15,979.75 ... (NASDAQ:VKTX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 74% ownership. That ...VKTX Related ETFs ; VTI, 0%, +3.43% ; Total Stock Market ETF Vanguard ; DWAS, 0.82%, -2.47% ; DWA Smallcap Momentum Invesco ETF ...As of May 11, 2023, the average one-year price target for Viking Therapeutics is 29.89. The forecasts range from a low of 23.23 to a high of $36.75. The average price target represents an increase ...Mar 29, 2023 · Viking Therapeutics (VKTX 4.42%), a small-cap biotech, has been on quite the ride over the past few months.Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival ...
Find real-time VKTX - Viking Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.What happenedShares of the metabolic disease specialist Viking Therapeutics (NASDAQ: VKTX) were up by 6.6% on slightly below-average volume as of 1:56 p.m. ET Wednesday afternoon. The biotech's ...(NASDAQ: VKTX) Viking Therapeutics's market cap is $978.28M, as of Nov 12, 2023. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Viking Therapeutics 's market cap is calculated by multiplying VKTX 's current stock price of $9.78 by VKTX 's total outstanding shares of 100,028,953 .Instagram:https://instagram. robinhood chartsbest workers comp insurance californiaxbi holdingsbest rated forex brokers May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease. With ... oil stocksaalgx Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Oct 25, 2023Dec 14, 2022 · Viking Therapeutics (NASDAQ:VKTX) is a great speculative biotech play to look into. The reason why I state that is because I believe it has huge potential as a long-term play. dividends calculator Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share.All thanks to its potential treatment for obesity, VK2735. So far, we know it works ...Viking Therapeutics said VK2809 met the main goal of a phase 2b trial by showing statistically significant reductions in liver fat in patients with NASH. VKTX +12% yesterday, @CR144 Research ...The latest price target for Viking Therapeutics ( NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023. The analyst firm set a price target for 32.00 expecting VKTX to rise ...